论文部分内容阅读
本文报告以我校自制的新抗疟药磷酸羟基喹哌在动物和人体试验证明毒性较低並对鼠疟和猴疟治疗有效后,首次于1974年11～12月对现症疟疾患者试治的临床结果(以相同剂量氯喹作对照)。治疗组44例(恶性疟30例,间日疟14例)于一疗程全部治愈,半数患者随访一月未见复发。平均退热时间及平均原虫转阴时间对恶性疟与间日疟均较对照组为短。对照组19例(恶性疟12例,间日疟7例),痊愈17例,2例分别于治疗开始后第5天和第6天再现原虫血症。不同年龄组以不同剂量治疗效果相同。磷酸羟基喹哌对胃肠道刺激较小;对造血系统无明显毒性反应;心电图观察除治疗组有4例窦性心动过缓外,未见其他异常。
This report reports that our school-made new antimalarial drug hydroxyphosphaquiphyzotoxin has been shown to be less toxic and effective in the treatment of murine malaria and macaque in animal and human trials. The trial was first conducted in November-December 1974 on malaria patients The clinical results (with the same dose of chloroquine as a control). In the treatment group, 44 cases (30 cases of Plasmodium falciparum and 14 cases of Plasmodium vivax) were cured in one course of treatment, and no recurrence was observed in half of the patients at one month of follow-up. The average time of antipyretic and the average protozoa negative time were shorter than those of the control group for falciparum malaria and Plasmodium vivax. In the control group, 19 cases (12 cases of falciparum malaria and 7 cases of Plasmodium vivax) cured 17 cases, and 2 cases recovered parasitemia on day 5 and 6 respectively. Different age groups with different doses of the same treatment. Hydroxyquipotassium phosphate less irritating to the gastrointestinal tract; No obvious toxic reaction to the hematopoietic system; Electrocardiogram except for the treatment group, 4 cases of sinus bradycardia, no other abnormalities.